OBJECTIVE: Thromboembolus can occur during endovascular coil embolization. The aim of our study was to show our experience of intraarterial (IA) tirofiban infusion for thromboembolism during coil embolization for ruptured intracranial aneurysms. METHODS: This retrospective analysis was conducted in 64 patients with ruptured aneurysms who had emergent endovascular coil embolization from May 2007 to April 2011 at a single institute. Thromboembolic events were found in ten patients (15.6%). Anticoagulation treatment with intravenous heparin was started after the first coil deployment in ruptured aneurysmal sac. When a thrombus or embolus was found during the procedure, we tried to resolve them without delay with an initial dosage of 0.3 mg of tirofiban up to 1.2 mg. RESULTS: Three patients of four with total occlusion had recanalizations of thrombolysis in myocardial infarction (TIMI) grade III and five of six with partial occlusion had TIMI grade III recanalizations. Eight patients showed good recovery, with modified Rankin Scale (mRS) score of 0 and one showed poor outcome (mRS 3 and 6). There was no hemorrhagic or hematologic complication. CONCLUSION: IA tirofiban can be feasible when thromboembolic clots are found during coil embolization in order to get prompt recanalization, even in patients with subarachnoid hemorrhage.
OBJECTIVE: Thromboembolus can occur during endovascular coil embolization. The aim of our study was to show our experience of intraarterial (IA) tirofiban infusion for thromboembolism during coil embolization for ruptured intracranial aneurysms. METHODS: This retrospective analysis was conducted in 64 patients with ruptured aneurysms who had emergent endovascular coil embolization from May 2007 to April 2011 at a single institute. Thromboembolic events were found in ten patients (15.6%). Anticoagulation treatment with intravenous heparin was started after the first coil deployment in ruptured aneurysmal sac. When a thrombus or embolus was found during the procedure, we tried to resolve them without delay with an initial dosage of 0.3 mg of tirofiban up to 1.2 mg. RESULTS: Three patients of four with total occlusion had recanalizations of thrombolysis in myocardial infarction (TIMI) grade III and five of six with partial occlusion had TIMI grade III recanalizations. Eight patients showed good recovery, with modified Rankin Scale (mRS) score of 0 and one showed poor outcome (mRS 3 and 6). There was no hemorrhagic or hematologic complication. CONCLUSION: IA tirofiban can be feasible when thromboembolic clots are found during coil embolization in order to get prompt recanalization, even in patients with subarachnoid hemorrhage.
Authors: Daniel W Bougie; Peter R Wilker; Elizabeth D Wuitschick; Brian R Curtis; Mohammad Malik; Stewart Levine; Richard N Lind; Jaime Pereira; Richard H Aster Journal: Blood Date: 2002-09-15 Impact factor: 22.113
Authors: Joon K Song; Yasunari Niimi; Patricia M Fernandez; Jonathan L Brisman; Razvan Buciuc; Mark J Kupersmith; Alejandro Berenstein Journal: AJNR Am J Neuroradiol Date: 2004-08 Impact factor: 3.825
Authors: R H Aster; B R Curtis; D W Bougie; S Dunkley; A Greinacher; T E Warkentin; B H Chong Journal: J Thromb Haemost Date: 2006-03 Impact factor: 5.824
Authors: Jean-Christophe Gentric; Joelle Brisson; André Lima Batista; Jimmy Ghostine; Jean Raymond; Daniel Roy; Alain Weill Journal: Interv Neuroradiol Date: 2015-05-11 Impact factor: 1.610
Authors: Jacques Sedat; Yves Chau; Lydiane Mondot; Richard Chemla; Michel Lonjon; Bernard Padovani Journal: Neuroradiology Date: 2013-11-27 Impact factor: 2.804